Back to Results
First PageMeta Content
Proteins / Cell cycle / Apoptosis / Genes / B-cell chronic lymphocytic leukemia / CDK inhibitor / Poly ADP ribose polymerase / Cyclin-dependent kinase / Cyclin / Biology / Cell biology / Programmed cell death


AT7519, a Potent Multi-targeted CDK Inhibitor, is Active in CLL Patient Samples Independent of Stage 3161 V Lock1, L Cooke2, M Yule1, NT Thompson1, K Della Croce2, JF Lyons1,MS Squires1,D Mahadevan2. INTRODUCTION
Add to Reading List

Open Document

File Size: 162,44 KB

Share Result on Facebook

City

Tucson / Cambridge / /

Company

Therapeutics Ltd. / Astex Therapeutics Ltd. / /

Country

United Kingdom / /

Currency

pence / /

MedicalCondition

B-cell lymphoproliferative disorders / ACTIVITY OF AT7519 IN CLL PATIENT SAMPLES Chronic / lymphocytic leukemia / diseases / disease / MS / /

Organization

2Arizona Cancer Center / American Society for Hematology / /

Person

Rai Stage / /

Position

representative / consultant / /

ProvinceOrState

Aurora / Arizona / /

Technology

antibodies / apoptosis / /

URL

www.astex-therapeutics.com / /

SocialTag